Phase 3 trial results suggest pimavanserin tempers psychosis in people with Parkinson’s.
New regulatory initiatives will soon make clinical trial data more publicly available than ever, but industry and other groups warn that the move could endanger patient privacy and lead to misuse of data.
A mouse with TDP-43 proteinopathy looks to be an unlikely model for testing amyotrophic lateral sclerosis drugs.
A gene therapy approach to protect cholinergic neurons appeared safe and seemed to stabilize brain metabolism in a Phase 1 trial of AD patients.
Once branded as a difficult target, β-secretase has become the crowd favorite. But might pharma have to cool its jets?
As new substrates and functions for BACE continue to emerge, scientists worry about adverse effects of blocking the protease.
Researchers at a meeting on BACE shared concerns that blocking the protease in adults might have unexpected consequences.
Researchers at BACE meeting explore how trafficking and degradation of the protease relate to amyloid pathology in AD.
Scientists are trying to help the brain replace lost dopamine in people with Parkinson's. Will gene therapy or cell replacement work eventually?
A Keystone symposium underscores the role of lysosomal dysfunction and vesicle trafficking in neurodegenerative disease.
A proof-of-concept study suggests that amyloid imaging will offer insights into traumatic brain injury.
A deletion in chromosome 22 points to new genetic risk factors for Parkinson's disease.
A parkinsonism-associated ubiquitin ligase interacts with parkin to promote mitophagy.
Epilepsy’s ties with Alzheimer’s disease occur earlier than previously thought.
Rare variants of AD share some common areas of brain atrophy, but are also unique by way of degeneration in specific functional networks that correspond with clinical symptoms.